//www.igerbera.com/journals/jamadermatology en-us Wed, 01 Mar 2023 00:00:00 GMT 结婚,2023年3月15日11:43:36格林尼治时间 Silverchair jamams@jamanetwork.org support@www.igerbera.com //www.igerbera.com/journals/jamadermatology/fullarticle/2801894 Wed, 01 Mar 2023 00:00:00 GMT In the Original Investigation titled “Association of Lipid-Lowering Drugs With Risk of Psoriasis: A Mendelian Randomization Study,” there was an error in the line “Psoriasis (FinnGen)” in Figure 1. The upper limit of the 95% CI was written as “1.91” but should be “0.91.” The article has been corrected online. 159 3 344 344 10.1001/jamadermatol.2023.0470 2801894 //www.igerbera.com/journals/jamadermatology/fullarticle/2801876 Wed, 01 Mar 2023 00:00:00 GMT Mission Statement: JAMA Dermatology’s mission is to elevate the art and science of health and diseases of skin, hair, nails, and mucous membranes, and their treatment, to enable dermatologists to deliver evidence-based, high-value medical and surgical dermatologic care. The journal publishes a broad range of innovative studies and trials that shift research and clinical practice paradigms, expand the understanding of the burden of dermatologic diseases and key outcomes, improve the practice of dermatology, and ensure equitable care to all patients. The journal also features research and opinion examining ethical, moral, socioeconomic, educational, and political issues relevant to dermatologists to enable ongoing improvement to the workforce, scope of practice, and the training of future dermatologists. JAMA Dermatology aims to be a leader in developing initiatives to improve diversity, equity, and inclusion within the specialty and within dermatology medical publishing. 159 3 244 244 10.1001/jamadermatol.2022.4404 2801876 //www.igerbera.com/journals/jamadermatology/fullarticle/2800961 Wed, 01 Mar 2023 00:00:00 GMT This cohort study assesses the cutaneous and systemic manifestations of systemic sclerosis. 159 3 308 313 10.1001 / jamadermatol.2022.6330 2800961 //www.igerbera.com/journals/jamadermatology/fullarticle/2800960 Wed, 01 Mar 2023 00:00:00 GMT A woman in her 60s presents with a pruritic rash that initially developed on the legs and progressed to her feet, arms, hands, and trunk, with associated symptoms of a burning sensation and occasional pain. What is your diagnosis? 159 3 333 334 10.1001/jamadermatol.2022.6349 2800960 //www.igerbera.com/journals/jamadermatology/fullarticle/2800959 Wed, 01 Mar 2023 00:00:00 GMT A woman in her 30s presents with a bruise on her hand with a blue-green plaque that appeared after a twisting injury to the affected hand. What is your diagnosis? 159 3 335 336 10.1001/jamadermatol.2022.6356 2800959 //www.igerbera.com/journals/jamadermatology/fullarticle/2800958 Wed, 01 Mar 2023 00:00:00 GMT Development of robust measures to monitor disease status and evaluate therapeutic impacts is central to improving patient outcomes. However, differentiating activity and damage in morphea is challenging. In this issue of JAMA Dermatology, García-Romero et al report the development of the Morphea Activity Measure (MAM), an instrument designed to capture disease activity in pediatric morphea. Using Delphi consensus methods, 14 experts agreed on a 10-item tool. The final items were new lesions, enlarging lesions, progressive atrophy in linear lesions, erythema, violaceous rim, warmth, induration or edema, white-yellow or waxy appearance, shiny white wrinkling, and body surface area of active lesions at 7 body sites. The validity and reliability of the MAM were then tested by 8 of the original 14 experts in a cohort of 14 children with various morphea subtypes. 159 3 249 251 10.1001/jamadermatol.2022.6364 2800958 //www.igerbera.com/journals/jamadermatology/fullarticle/2800957 Wed, 01 Mar 2023 00:00:00 GMT This retrospective cohort study examines the association of lymphocyte and neutrophil levels with treatment outcomes in 147 patients with epidermal necrolysis in France. 159 3 338 340 10.1001/jamadermatol.2022.6262 2800957 //www.igerbera.com/journals/jamadermatology/fullarticle/2800956 Wed, 01 Mar 2023 00:00:00 GMT This case report describes a patient with recurrent epidermolysis bullosa acquisita who was treated with tofacitinib. 159 3 342 344 10.1001/jamadermatol.2022.6250 2800956 //www.igerbera.com/journals/jamadermatology/fullarticle/2800955 Wed, 01 Mar 2023 00:00:00 GMT This cohort study uses insurance claims data to estimate the 6-month rate of infections among children with psoriasis who started treatment with ustekinumab, etanercept, or methotrexate. 159 3 289 298 10.1001/jamadermatol.2022.6325 2800955 //www.igerbera.com/journals/jamadermatology/fullarticle/2800954 Wed, 01 Mar 2023 00:00:00 GMT This diagnostic study uses a Delphi consensus method to develop the Morphea Activity Measure, a scoring tool designed to evaluate morphea disease activity of any type and severity for use in clinical and research settings, and validates the tool among pediatric patients with morphea. 159 3 299 307 10.1001/jamadermatol.2022.6365 2800954 //www.igerbera.com/journals/jamadermatology/fullarticle/2800953 Wed, 01 Mar 2023 00:00:00 GMT This Viewpoint examines the inconsistencies in classification of cosmetic vs medical care and offers potential solutions to the issue of payers not providing coverage for skin conditions that have psychosocial effects. 159 3 245 246 10.1001/jamadermatol.2022.6322 2800953 //www.igerbera.com/journals/jamadermatology/fullarticle/2800881 Wed, 01 Mar 2023 00:00:00 GMT Atopic dermatitis (AD) is a pruritic, chronic inflammatory skin disease characterized by recurrent flares and a family history of atopy. A hallmark feature of AD is epidermal barrier dysfunction that activates type 2 immune cells, which release Th2 cytokines (IL-4, IL-13, IL-31, and IL-22) that promote inflammation, B-cell IgE class switching, and epidermal hyperplasia. Erythrodermic AD is a severe clinical subtype, characterized by marked erythema, severe pruritus, and scaling of extensively affected skin (≥90% body surface area). A high risk of infection accompanies erythrodermic AD because inflammation, fissuring, and excoriation increases susceptibility to bacteria and other microbes. 159 3 247 248 10.1001/jamadermatol.2022.6162 2800881 //www.igerbera.com/journals/jamadermatology/fullarticle/2800880 Wed, 01 Mar 2023 00:00:00 GMT This post hoc analysis of 6 randomized, double-blind, placebo-controlled trials assesses the efficacy and safety of dupilumab in patients with erythrodermic atopic dermatitis. 159 3 255 266 10.1001/jamadermatol.2022.6192 2800880 //www.igerbera.com/journals/jamadermatology/fullarticle/2800634 Wed, 01 Mar 2023 00:00:00 GMT This mendelian randomization examines the association between genetically proxied lipid-lowering drugs and psoriasis risk. 159 3 275 280 10.1001/jamadermatol.2022.6051 2800634 //www.igerbera.com/journals/jamadermatology/fullarticle/2800633 Wed, 01 Mar 2023 00:00:00 GMT This systematic review and meta-analysis performs separate analyses of the prevalence of depressive and anxiety disorders and the prevalence of depressive and anxiety symptoms in patients with alopecia areata. 159 3 281 288 10.1001/jamadermatol.2022.6085 2800633 //www.igerbera.com/journals/jamadermatology/fullarticle/2800632 Wed, 01 Mar 2023 00:00:00 GMT This systematic review summarizes the values and preferences of patients and caregivers regarding the treatment of atopic dermatitis (eczema). 159 3 320 330 10.1001/jamadermatol.2022.6045 2800632 //www.igerbera.com/journals/jamadermatology/fullarticle/2800345 Wed, 01 Mar 2023 00:00:00 GMT This case report describes a large, purpuric plaque involving most of the right face with associated periorbital swelling but without ulceration. 159 3 332 332 10.1001/jamadermatol.2022.5446 2800345 //www.igerbera.com/journals/jamadermatology/fullarticle/2800344 Wed, 01 Mar 2023 00:00:00 GMT This comparative effectiveness research study assesses the discriminatory ability of diagnostic criteria for pyoderma gangrenosum. 159 3 337 338 10.1001/jamadermatol.2022.5978 2800344 //www.igerbera.com/journals/jamadermatology/fullarticle/2800343 Wed, 01 Mar 2023 00:00:00 GMT This cohort study examines the prevalence of positive patch test reactions to methylchloroisothiazolinone/methylisothiazolinone combination and methylisothiazolinone alone in North America and Europe. 159 3 267 274 10.1001/jamadermatol.2022.5991 2800343 //www.igerbera.com/journals/jamadermatology/fullarticle/2800237 Wed, 01 Mar 2023 00:00:00 GMT This case report describes friable erythematous plaques on the neck, inguinal folds, buttocks, bilateral axillae, and bilateral antecubital fossae. 159 3 331 331 10.1001/jamadermatol.2022.5117 2800237 //www.igerbera.com/journals/jamadermatology/fullarticle/2800235 Wed, 01 Mar 2023 00:00:00 GMT This Patient Page describes the symptoms, diagnosis, and treatment of drug reaction with eosinophilia and systemic symptoms. 159 3 348 348 10.1001/jamadermatol.2022.4519 2800235 //www.igerbera.com/journals/jamadermatology/fullarticle/2800121 Wed, 01 Mar 2023 00:00:00 GMT This case report describes a woman in her 60s flesh-colored papules that were localized to the central face and a lobular downgrowth of cells with clear, expanded, faintly glassy cytoplasm. 159 3 340 342 10.1001/jamadermatol.2022.5701 2800121

map